Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2000
10/26/2000WO2000063379A2 The p2x3 receptor, methods of altering p2x3 receptor activity and uses thereof
10/26/2000WO2000063376A1 Adipocyte complement related protein homolog zacrp2
10/26/2000WO2000063370A2 Nucleic acids coding for novel truncated cart proteins, corresponding truncated cart polypeptides and their use for therapeutic and diagnostic purposes
10/26/2000WO2000063367A1 A novel family of beta sub-unit proteins from a voltage-gated sodium channel, nucleic acids encoding them and therapeutic or diagnostic uses thereof
10/26/2000WO2000063249A1 Polypeptides derived from endostatin exhibiting antiangiogenic activity
10/26/2000WO2000063241A2 Methods and compositions for modulating an immune response
10/26/2000WO2000063230A2 49 human secreted proteins
10/26/2000WO2000063210A1 Morphinoid compounds
10/26/2000WO2000063209A1 New compounds, their preparation and use
10/26/2000WO2000063208A1 Substituted imidazoles, their preparation and use
10/26/2000WO2000063204A2 Substituted azoles
10/26/2000WO2000063203A1 Piperidine-indole compounds having 5-ht6 affinity
10/26/2000WO2000063197A1 Hydroxamic acid derivative
10/26/2000WO2000063194A1 Sulfonamide derivatives having oxadiazole rings
10/26/2000WO2000063191A1 Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
10/26/2000WO2000063190A1 New compounds, their preparation and use
10/26/2000WO2000063187A1 Fab i inhibitors
10/26/2000WO2000063181A1 Use of maduraphthalazine derivatives as inhibitors of pro-inflammatory cytokins
10/26/2000WO2000063178A1 Dibenzoazulene derivatives for treating thrombosis, osteoporosis, arteriosclerosis
10/26/2000WO2000063175A2 Novel process
10/26/2000WO2000063171A1 Tricyclic compounds
10/26/2000WO2000063170A1 Cyclobutene-3,4-dione derivatives as inhibitors of phosphodiesterase 5
10/26/2000WO2000063167A1 Crystalline forms of the sodium salt of 5- chloro -2- methoxy -n- (2- (4-methoxy -3- methyl aminothio carbonylamino sulfonylphenyl) ethyl) benzamide
10/26/2000WO2000063165A1 Mmp inhibitor
10/26/2000WO2000063161A1 Ppar-(gamma) agonists as agents for the treatment of type ii diabetes
10/26/2000WO2000063153A1 New compounds, their preparation and use
10/26/2000WO2000062819A1 Formulations for detecting asthma
10/26/2000WO2000062818A1 Differentiation of monocytes into functional dendritic cells
10/26/2000WO2000062809A1 Proliferation inhibitor for androgen-independent tumor
10/26/2000WO2000062806A1 Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid
10/26/2000WO2000062800A2 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
10/26/2000WO2000062799A1 Hcv combination therapy, containing ribavirin in association with antioxidants
10/26/2000WO2000062791A1 D-form polypeptide which induces immune tolerance and methods of use
10/26/2000WO2000062789A1 Peptide extract of lupine and pharmaceutical or cosmetic or nutritional composition comprising same
10/26/2000WO2000062781A1 Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk
10/26/2000WO2000062780A1 Use of glucosylceramide synthesis inhibitors in therapy
10/26/2000WO2000062779A1 Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy
10/26/2000WO2000062778A1 Cyclic protein tyrosine kinase inhibitors
10/26/2000WO2000062767A2 Pharmaceutical compositions containing pyridine or pyrimidine derivates for inhibition of cytokine production and secretion
10/26/2000WO2000062764A1 Gum pad for delivery of medication to mucosal tissues
10/26/2000WO2000062744A2 Skin care compositions containing combination of skin care actives
10/26/2000WO2000062735A2 Treatment of neoplasms with viruses
10/26/2000WO2000047607B1 A synthetic peptide disturbing intracellular signaling
10/26/2000WO2000039275A3 Multiple shear stress responsive elements (ssre) and methods of use thereof
10/26/2000WO2000039120A3 Compounds and methods for modulation of estrogen receptors
10/26/2000WO2000037099A3 Method for accelerating the rate of mucociliary clearance by using a kunitz-type serine protease inhibitor
10/26/2000WO2000037061A3 cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION
10/26/2000WO2000035919A3 Quinoline derivatives
10/26/2000WO2000035886A3 (hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
10/26/2000WO2000031120A3 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis
10/26/2000WO2000028045A3 Human hydrolase proteins
10/26/2000WO2000027815A3 N-substituted azacycles, their preparation and their use as orl-1 receptor ligands
10/26/2000WO2000026197A9 Novel inhibitors of impdh enzyme
10/26/2000WO2000021508A3 Novel therapeutic use of compounds with beta-3-agonist activity
10/26/2000WO2000017191A3 N-(iminomethyl)amine derivatives, their preparation, their use as medicines and compositions containing them
10/26/2000WO2000007577A3 Phosphatidylcholine as a medicament for the protection of mucosa
10/26/2000WO2000004012A9 COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF
10/26/2000DE19918211A1 New 2-carbocyclyl-benzimidazole-carboxamide derivatives, are PARP inhibitors useful e.g. for treating neurodegenerative disease, epilepsy, ischemia, tumors, inflammation or diabetes
10/26/2000CA2373359A1 Nucleic acids coding for novel truncated cart proteins, corresponding truncated cart polypeptides and their use for therapeutic and diagnostic purposes
10/26/2000CA2371976A1 A novel family of beta sub-unit proteins from a voltage-gated sodium channel, nucleic acids encoding them and therapeutic or diagnostic uses thereof
10/26/2000CA2370742A1 Ppar-(gamma) agonists as agents for the treatment of type ii diabetes
10/26/2000CA2370659A1 The p2x3 receptor, methods of altering p2x3 receptor activity and uses thereof
10/26/2000CA2370602A1 Adipocyte complement related protein homolog zacrp2
10/26/2000CA2370417A1 Substituted azoles
10/26/2000CA2370268A1 Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid
10/26/2000CA2370246A1 Vascular endothelial cell growth factor variants and uses thereof
10/26/2000CA2370129A1 Methods and compositions for modulating an immune response
10/26/2000CA2369961A1 Polypeptides derived from endostatin exhibiting antiangiogenic activity
10/26/2000CA2369078A1 Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk
10/26/2000CA2368839A1 D-form polypeptide which induces immune tolerance and methods of use
10/26/2000CA2367395A1 Cyclic amine derivatives and use thereof
10/26/2000CA2367359A1 Dibenzoazulene derivatives for the treatment of thrombosis, osteoporosis, arteriosclerosis
10/26/2000CA2367356A1 New compounds, their preparation and use
10/26/2000CA2365449A1 Inhibitor of the growth of androgen-independent tumor
10/26/2000CA2364209A1 49 human secreted proteins
10/26/2000CA2363994A1 Diagnosis of a person's risk for developing atherosclerosis or diabetic retinopathy
10/25/2000EP1046711A2 Recombinant adeno-associated virus
10/25/2000EP1046399A1 HCV combination therapy, containing ribavirin in association with antioxidants
10/25/2000EP1045906A1 Apo-2 ligand
10/25/2000EP1045897A1 Enzyme catalyzed therapeutic agents
10/25/2000EP1045863A1 Detoxication of active pharmaceutical substances using cyclodextrine oligomers
10/25/2000EP1045862A1 Polypeptides, dna coding therefor, formulations thereof, and their use in inhibiting factor xii activation
10/25/2000EP1045853A1 Synthesis of combretastatin a-4 prodrugs and trans-isomers thereo f
10/25/2000EP1045850A1 Purine compounds having pde iv inhibitory activity and methods of synthesis
10/25/2000EP1045849A1 Purine derivatives having phosphodiesterase iv inhibition activity
10/25/2000EP1045846A1 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
10/25/2000EP1045845A1 N-oxides of heterocyclic compounds with tnf and pde-iv inhibiting activity
10/25/2000EP1045842A2 Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
10/25/2000EP1045839A2 Novel amines as pharmaceutical agents
10/25/2000EP1045836A1 Pyridones as src family sh2 domain inhibitors
10/25/2000EP1045834A1 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
10/25/2000EP1045833A1 2,3-substituted indole compounds as cox-2 inhibitors
10/25/2000EP1045701A1 Methods of using human receptor protein 4-1bb
10/25/2000EP1045697A2 Extension of cellular lifespan, methods and reagents
10/25/2000EP1045694A1 Method of increasing bone volume using non-naturally-occurring fp selective agonists
10/25/2000EP1045693A1 Aminophenoxyacetic acid derivatives as neuroprotectants
10/25/2000EP1045691A1 Statin-carboxyalkylether combinations
10/25/2000EP1045690A1 Benzenesulfonamide inhibitors of pde-iv and their therapeutic use
10/25/2000EP1045637A1 Decorated red blood cells
10/25/2000EP0750626B1 Corpuscles of stannius protein, stanniocalcin
1 ... 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 ... 1564